Clinical Trial Update: Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating LMB-100 alone or with nab-paclitaxel in previously treated metastatic and/or locally advanced pancreatic ductal adenocarcinoma and me…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms
• Pancreatic Ductal Adenocarcinoma
• Pancreatic Neoplasms

Drugs mentioned

• LMB-100 (mesothelin-targeted immunotoxin)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neoplasms, Pancreatic Neoplasms | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-02-02